Sign Out
Fulvestrant is indicated for the: Treatment of hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
Treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
Continue with Google